N. Babović

发表

Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients

G. Konjević, V. Jović, A. Vuletić, 2007, Clinical & Experimental Metastasis.

Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: Decreased NKG2D and increased CD158a receptors on CD3–CD16+ NK cells

G. Konjević, I. Spuẑić, V. Jurišić, 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia--the Melanoma Focus Study.

M. Novaković, D. Mihajlović, M. Marinković, 2015, Vojnosanitetski pregled.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European Journal of Cancer.

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting

I. Soldatovic, N. Babović, P. Nikić, 2022, Frontiers in Oncology.

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients

G. Konjević, N. Tanić, V. Jurišić, 2014, Melanoma research.

AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).

F. Cavalli, A. Kuten, M. Aapro, 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

G. Konjević, V. Jurišić, R. Dzodic, 2015, Journal of Translational Medicine.

Primary non-Hodgkin lymphoma of the breast. Is it possible to avoid mastectomy?

S. Jelić, N. Babović, V. Jovanovic, 2000, Journal of experimental & clinical cancer research : CR.

Serum Gonadotropin Levels in Patients with Germ-Cell Tumors of the Testis: Interrelations, Possible Cross-Reactions and Interpretation of Beta-Hcg Level

N. Babović, V. Kovčin, S. Jelic, 1997, The International journal of biological markers.

The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.

G. Konjević, K. M. Mirjačić Martinović, N. Babović, 2011, The Journal of surgical research.

Evaluation of the Functional Capacity of NK Cells of Melanoma Patients in an In Vitro Model of NK Cell Contact with K562 and FemX Tumor Cell Lines

A. Krivokuca, R. Janković, G. Konjević, 2017, The Journal of Membrane Biology.

Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma

T. Srdić-Rajić, G. Konjević, V. Jurišić, 2015, Journal of Clinical Pathology.

Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels

G. Konjević, V. Jurišić, R. Dzodic, 2016, Melanoma research.

Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy

A. Vuletić, V. Jurišić, D. Gavrilovic, 2023, Journal of clinical pathology.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

J. Blay, G. Demetri, A. Tolcher, 2015, The Lancet. Oncology.

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.

S. Radulović, S. Jelić, D. Gavrilovic, 2001, Lung cancer.

Increased circulating TGF-β1 is associated with impairment in NK cell effector functions in metastatic melanoma patients

T. Srdić-Rajić, A. Vuletić, V. Jurišić, 2022, Growth factors.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European journal of cancer.

Interleukin-4-induced natural killer cell antitumor activity in metastatic melanoma patients

A. Krivokuca, A. Larsen, K. Martinovic, 2020, European Cytokine Network.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

I. Zalaudek, A. Hauschild, R. Dummer, 2017, European journal of cancer.

Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.

S. Jelić, D. Gavrilovic, L. Stamatović, 2002, European journal of cancer.

Antimelanoma immunity in vitiligo and melanoma patients.

T. Stanojković, R. Dzodic, Z. Juranić, 2003, Neoplasma (Bratislava).

In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients

G. Konjević, A. Vuletić, N. Babović, 2010, Melanoma research.

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study

S. Jelić, N. Babović, N. Milanović, 2002, Melanoma research.

A pilot study to assess the efficacy of salmon calcitonin in the relief of neuropathic pain caused by extraskeletal metastases

S. Jelić, N. Babović, Z. Tomašević, 2004, Supportive Care in Cancer.

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.

S. Jelić, N. Babović, N. Milanović, 1997, European journal of cancer.

In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.

G. Konjević, A. Vuletić, N. Babović, 2012, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

G. Konjević, V. Jurišić, R. Dzodic, 2015, Journal of Translational Medicine.

Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures

S. Jelić, L. Stamatović, N. Babović, 2001, Medical oncology.

Evaluation of the Functional Capacity of NK Cells of Melanoma Patients in an In Vitro Model of NK Cell Contact with K562 and FemX Tumor Cell Lines

A. Krivokuca, R. Janković, G. Konjević, 2017, The Journal of Membrane Biology.

[Levels of immune complexes in fresh and frozen serum and plasma detected by precipitation with polyethylene glycol in patients with malignant diseases].

Z. Juranić, N. Babović, Z. Tomašević, 1997, Srpski Arhiv za Celokupno Lekarstvo.

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients

A. Vuletić, V. Jurišić, N. Babović, 2023, Innate immunity.

Cancer in the elderly: A challenge for 21st century

N. Babović, T. Ursulovic, B. Jelic, 2002 .